Bakhtawar Bai and Aaila Parvez have published a letter to the editor in the Egyptian Journal of Neurosurgery, offering a detailed critique of a recent retrospective cohort study on brain tumors in infancy and early childhood. The original study, published on 16 July 2026, focused on clinical presentation, histopathological diagnosis, overall survival, and the postoperative effects of adjuvant chemotherapy and radiotherapy in a low- and middle-income country. Bai and Parvez express interest in the work, noting it is one of the first studies in the subcontinent to address these specific aspects of pediatric neuro-oncology. However, they identify several methodological limitations that they argue affect the generalizability and precision of the reported findings.
The authors first address the retrospective design of the original study, pointing out that its single-center nature may have introduced selection bias. They argue that the mortality and complication rates reported in the study cannot be generalized to the wider population. Furthermore, the extent of resection and the administration of adjuvant therapy were determined by tumor characteristics rather than through randomization. This lack of randomization makes it difficult to determine whether improved survival rates were attributable to the treatment itself or to the favorable characteristics of the tumors. Additionally, the study spanned over 11 years, a period during which diagnostic techniques and treatment approaches may have evolved, potentially introducing variability that influenced the outcomes.
A second point of critique concerns the classification of tumor types. The original study mentioned medulloblastoma, ependymoma, and diffuse gliomas. Bai and Parvez note that the current World Health Organization classification of pediatric central nervous system tumors integrates molecular features into risk stratification, management plans, and diagnosis. While histopathology remains the basis for diagnosis, they argue that incomplete molecular profiling may limit the precision of tumor classification and the optimization of management. They suggest that filtering out which tumors underwent molecular testing and profiling would improve the study’s outcomes and diagnostic accuracy.
The authors also highlight the relatively small sample size of the original study, which included 50 patients. They contend that this small number contributes to the risk of developing a Type II error and may not be statistically sufficient for the study’s claims. As a single-center cohort, the outcomes might not cover a broader pediatric population, affecting the generalizability of the reported characteristics and findings. The letter suggests that more representative cohorts with multicenter studies would be beneficial in providing valid and reliable estimates with proper precision.
Another significant limitation identified is the lack of assessment of long-term neurocognitive outcomes and quality of life. While the original study assessed overall survival and progression-free survival, it did not consistently evaluate long-term neurological functions. Bai and Parvez emphasize that children younger than three years are at a critical age of brain development, meaning survival alone should not be considered the best outcome. Clinicians must assess whether patients experience developmental delays, cognitive impairment, motor deficits, or other neurological disabilities. The study does not clarify whether the treatment improved survival or also preserved long-term neurological functions and enhanced quality of life.
In their conclusion, Bai and Parvez commend the authors of the original article for presenting a rare, informative, and educational study. They acknowledge that the work adds useful insights into histopathological diagnosis and the postoperative effects of adjuvant therapies in children with brain tumors. The letter argues that further emphasis on selecting a broader sample population to avoid bias and unfair selection, along with the assessment of long-term outcomes and postoperative quality of life, will enhance diagnostic accuracy and optimize clinical decision-making in similar cases.
The authors believe that continued documentation of such cases will strengthen the evidence base to improve clinical competence in managing these rare tumors.
This critique underscores the importance of considering molecular features in tumor classification and the necessity of evaluating long-term quality of life in pediatric patients. The authors’ suggestions for multicenter studies and larger sample sizes aim to address the generalizability issues inherent in single-center retrospective designs.
Subject of Research: Methodological critique of a retrospective cohort study on brain tumors in infancy and early childhood
Article Title: Comments on “Brain tumors in infancy and early childhood; a retrospective cohort study from a low-and middle-income country”
Article References: Bai, B., & Parvez, A. (2026). Comments on “Brain tumors in infancy and early childhood; a retrospective cohort study from a low-and middle-income country”. Egyptian Journal of Neurosurgery, 41(1), Article 156. https://doi.org/10.1186/s41984-026-00662-3
Image Credits: AI Generated
DOI: 10.1186/s41984-026-00662-3
Keywords: pediatric brain tumors, retrospective cohort study, clinical methodology, neuro-oncology, low and middle income countries, molecular classification, quality of life, research critique, Comments, Brain, tumors, infancy
News Source: Cassandra Pierce. (November 8, 2026). Researchers Critique Pediatric Brain Tumor Study Design. Scienmag.



